Patents for A61P 35 - Antineoplastic agents (221,099)
10/2014
10/28/2014US8871708 Compositions and methods for treating AIDS or cancer by inhibiting the secretion of microparticles
10/28/2014US8871436 Immunostimulatory oligonucleotides and uses thereof
10/28/2014US8871253 Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt
10/28/2014US8871193 Viral vectors and their use in therapeutic methods
10/23/2014US20140315978 Compositions and Methods for Treatment of Prostate and Other Cancers
10/23/2014US20140314714 Immunopotentiative composition
10/21/2014US8865726 Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
10/21/2014US8865720 Sulfonyl-derivatives as novel inhibitors of histone deacetylase
10/21/2014US8865709 Aminooxazole inhibitors of cyclin dependent kinases
10/21/2014US8865690 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents
10/21/2014US8865686 Tetracycline compounds as tyrosyl-DNA phosphodiesterase I inhibitors
10/21/2014US8865663 Method for the administration of anti-cancer drugs
10/21/2014US8865656 Beta-hairpin peptidomimetics having CXCR4 antagonizing activity
10/21/2014US8865653 Method of treatment for immunogenic treatment resistant cancer
10/21/2014US8865652 Method of treating solid cancers with pegylated IL-10
10/21/2014US8865643 Recombinant surfactant protein D compositions and methods of use thereof
10/21/2014US8865642 Natural plant products for control of cancer metastasis
10/16/2014US20140309174 Hemiasterlin derivatives and uses thereof in the treatment of cancer
10/16/2014US20140308288 Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
10/14/2014US8859855 Chimeric PUFA polyketide synthase systems and uses thereof
10/14/2014US8859747 Promoters exhibiting endothelial cell specificity and methods of using same
10/14/2014US8859745 Promoters exhibiting endothelial cell specificity and methods of using same
10/14/2014US8859729 Growth hormone releasing peptides
10/14/2014US8859723 Peptidomimetic macrocycles
10/14/2014US8859594 Polymorphs of N-(6-(4-chlorophenoxy)hexyl)-N′-cyano-N″-(4-pyridyl)guanidine, and preparation thereof and use thereof
10/14/2014US8859574 Compounds and compositions as kinase inhibitors
10/14/2014US8859546 Picolinamide inhibitors of kinases
10/14/2014US8859488 Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
10/09/2014WO2014165786A1 Cabozantinib dosage form and use in the treatment of cancer
10/09/2014WO2014165779A1 Drug combinations to treat cancer
10/09/2014WO2014165736A2 Esters of 2-deoxy-monosaccharides with anti proliferative activity
10/09/2014WO2014165718A1 Combination therapy for the treatment of proliferative diseases
10/09/2014WO2014165714A1 Specific pomegranate juice compoments and inhibition of prostate cancer progression/metastasis
10/09/2014WO2014165581A1 Gpr15-mediated homing and uses thereof
10/09/2014WO2014165482A1 Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
10/09/2014WO2014165296A1 Methods and formulations to achieve tumor targeted double stranded rna mediated cell death
10/09/2014WO2014165103A1 Individualized high-purity glioblastoma multiforme stem cells and methods for stimulating immune response
10/09/2014WO2014165101A1 Individualized high purity colon carcinoma stem cells, methods and use of the same
10/09/2014WO2014164988A1 Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications
10/09/2014WO2014164942A1 Dual mek/pi3k inhibitors and therapeutic methods using the same
10/09/2014WO2014164784A1 Hdac inhibitor polymorphic forms and methods of use
10/09/2014WO2014164780A1 Fused tetracyclic bromodomain inhibitors
10/09/2014WO2014164771A1 Bromodomain inhibitors
10/09/2014WO2014164729A1 Substituted tricyclic pyrazolo-pyrimidine compounds
10/09/2014WO2014164596A1 Bet bromodomain inhibitors and therapeutic methods using the same
10/09/2014WO2014164558A1 Pyridinyl and fused pyridinyl triazolone derivatives
10/09/2014WO2014164554A1 Chemotherapy-resistant immune cells
10/09/2014WO2014164464A1 High purity ovarian cancer stem cells for active autologous immune therapy
10/09/2014WO2014164462A1 Method of induction and purification of a cell population responsible for vasculary mimicry and use of the same
10/09/2014WO2014164396A1 Ablative immunotherapy
10/09/2014WO2014164395A1 Combination anti-estrogen receptor cancer therapy using muc1 peptides and chemotherapeutics
10/09/2014WO2014164394A1 Combination anti-her2 cancer therapy using muc1 peptides and chemotherapeutics
10/09/2014WO2014163535A1 Chimeric peptide and pharmaceutical composition for treating oncological diseases
10/09/2014WO2014163513A1 Therapeutic compositions and uses thereof
10/09/2014WO2014163512A1 Therapeutic compositions comprising extracts of propolis and uses thereof
10/09/2014WO2014163278A1 Composition for protecting against radioactivity comprising fisetin compound as active ingredient
10/09/2014WO2014163101A1 Fc region variant
10/09/2014WO2014162962A1 Tumor antigen peptide
10/09/2014WO2014162039A1 Protein kinase inhibitors
10/09/2014WO2014161938A1 Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor
10/09/2014WO2014161845A1 Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
10/09/2014WO2014161808A1 Novel n-(2,3-dihydro-1h-pyrrolo[2,3-b]jpyridin-5-yl)-4- quinazolinamine and n-(2,3-dihydro-1h-indol-5-yl)-4- quinazolinamine derivatives as perk inhibitors
10/09/2014WO2014161240A1 Preparation method and application of anti-tumor active polypeptide component in scapharca subcrenatae
10/09/2014WO2014161046A1 Methods of treating diseases characterized by excessive wnt signalling
10/09/2014WO2014161037A1 Antibodies against human ryk and uses therefor
10/09/2014WO2014161031A1 Nanoparticles for drug delivery comprising albumin having a polymer chain coupled thereto
10/09/2014US20140303257 Use of EDG Receptor Binding Agents in Cancer
10/09/2014US20140303208 Pharmaceutically active piperidine derivatives
10/09/2014US20140303146 Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias
10/09/2014US20140303077 Albumin fusion proteins
10/09/2014US20140302499 Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
10/09/2014US20140302018 Treatment of diffuse large-cell lymphoma with anti-cd20 antibody
10/08/2014EP2787002A1 Oleanolic acid amidate derivatives, preparation methods and uses thereof
10/08/2014EP2787001A1 (E)-3-Aryl-3-oxoprop-1-enyl-2-phosphonic acid and its derivatives, methods for their preparation and their use
10/08/2014EP2786996A1 Purinone derivative hydrochloride
10/08/2014EP2786990A1 2-aminated methylene or 2-esterified methylene tanshinone derivatives, and preparation method and application thereof
10/08/2014EP2786989A1 2-alkyl-or-aryl-substituted tanshinone derivatives, and preparation method and application thereof
10/08/2014EP2786981A1 Stilbenoid compounds as inhibitors for squamous carcinoma and hepatoma and uses thereof
10/08/2014EP2786765A2 Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor
10/08/2014EP2786764A2 Combination therapy using anti-c-met antibody and sorafenib
10/08/2014EP2786757A1 2-substituted oleanolic acid derivative, method preparing for same, and application thereof
10/08/2014EP2786756A2 Combination therapy with an antitumor alkaloid
10/08/2014EP2786755A2 Combination therapy with an antitumor alkaloid
10/08/2014EP2786754A2 Combination therapy with an antitumor alkaloid
10/08/2014EP2786753A2 Combination therapy with an antitumor alkaloid
10/08/2014EP2786750A1 Agent for reducing adverse side effects of kinase inhibitor
10/08/2014EP2785872A2 Materials and methods related to nsaid chemoprevention in colorectal cancer
10/08/2014EP2785871A1 A ctc biomarker assay to combat breast cancer brain metastasis
10/08/2014EP2785842A1 Hpv chimaeric particle
10/08/2014EP2785766A1 Hydroxypolyamine salts
10/08/2014EP2785744A1 Protein inhibitors to complement and vegf pathways and methods of use thereof
10/08/2014EP2785743A1 Anti-ceacam1 recombinant antibodies for cancer therapy
10/08/2014EP2785742A1 Anti-kdr antibodies and methods of use
10/08/2014EP2785741A1 Antibodies against hgf - receptor and uses
10/08/2014EP2785738A1 Anti-npy and pyy antibodies and uses thereof
10/08/2014EP2785720A1 Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents
10/08/2014EP2785717A1 Pyrazolopyrrolidine compounds
10/08/2014EP2785714A1 Improved modulators of hec1 activity and methods therefor
10/08/2014EP2785712A1 Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof
10/08/2014EP2785701A2 Crystalline forms of carbazitaxel and process for preparation thereof
1 ... 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 ... 2211